Current problems in cancer. Case reports最新文献_第2页

Durable response to bispecific PD-1/ICOS antibody and ipilimumab in advanced microsatellite-stable colorectal cancer: a case report 双特异性PD-1/ICOS抗体和伊匹单抗在晚期微卫星稳定结直肠癌中的持久疗效：1例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-03-07 DOI: 10.1016/j.cpccr.2026.100414

Sarah Jung , Kelsey Gates , Hannah H Collins , Mosunmoluwa Oyenuga , Oluwadunni Emiloju , Lindsay M. Hannan , Olatunji B. Alese

{"title":"Durable response to bispecific PD-1/ICOS antibody and ipilimumab in advanced microsatellite-stable colorectal cancer: a case report","authors":"Sarah Jung , Kelsey Gates , Hannah H Collins , Mosunmoluwa Oyenuga , Oluwadunni Emiloju , Lindsay M. Hannan , Olatunji B. Alese","doi":"10.1016/j.cpccr.2026.100414","DOIUrl":"10.1016/j.cpccr.2026.100414","url":null,"abstract":"<div><div>Microsatellite-stable (MSS) or mismatch repair proficient (MMRp) colorectal cancer typically exhibits resistance to immune checkpoint blockade. Tumor mutational burden (TMB) and DNA repair defects may increase immunogenicity and sensitivity to novel immunotherapies. We present a patient with metastatic MSS colorectal adenocarcinoma, previously treated with multiple standard regimens, who demonstrated an exceptional and durable partial response to an investigational bispecific PD-1/ICOS antibody. XmAb23104 was initially given in combination with ipilimumab on a clinical trial (DUET-3) and subsequently via an expanded-access investigational new drug (IND) application. Genomic profiling revealed extremely high TMB and pathogenic BRCA1/2 mutations. He achieved a partial response which was sustained for >2 years without dose reductions. This case highlights a novel therapeutic opportunity for MSS CRC, in which high TMB and homologous recombination deficiency may sensitize tumors to bispecific checkpoint blockade. Further investigation of PD-1/ICOS bispecific antibodies in biomarker-selected MSS solid tumors is warranted.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"21 ","pages":"Article 100414"},"PeriodicalIF":0.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An atypical POEMS-like paraneoplastic syndrome associated with IgA κ smoldering multiple myeloma treated with daratumumab 用达拉单抗治疗IgA κ阴烧性多发性骨髓瘤相关的非典型poems样副肿瘤综合征

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-01-30 DOI: 10.1016/j.cpccr.2026.100407

Tanushree Bhatt , Bhuwan Bhatta , Alexander Johnston , Khin Pyai , Zainab Muslehuddin , Zyad Kafri

{"title":"An atypical POEMS-like paraneoplastic syndrome associated with IgA κ smoldering multiple myeloma treated with daratumumab","authors":"Tanushree Bhatt , Bhuwan Bhatta , Alexander Johnston , Khin Pyai , Zainab Muslehuddin , Zyad Kafri","doi":"10.1016/j.cpccr.2026.100407","DOIUrl":"10.1016/j.cpccr.2026.100407","url":null,"abstract":"<div><div>POEMS syndrome is a rare paraneoplastic disorder driven by an underlying plasma cell dyscrasia and characterized by polyneuropathy with multisystem features. Although most cases are associated with lambda light chains, kappa-restricted disease is uncommon. We report a woman with IgA kappa smoldering multiple myeloma who presented with long-standing, progressive sensorimotor neuropathy and systemic features including lymphadenopathy and cutaneous changes. Bone marrow biopsy demonstrated 10% kappa-restricted plasma cells with trisomy 5 and trisomy 9. She was started on daratumumab, lenalidomide, and dexamethasone; lenalidomide was discontinued after the first cycle due to hypersensitivity, and therapy continued with daratumumab plus dexamethasone for six total cycles. Treatment resulted in a very good partial response, with marked reduction of the IgA monoclonal protein, improvement in free light-chain ratio, and decreased marrow plasma cells to 5%. Clinically, neuropathy and functional symptoms improved within several months of cytoreduction. This case underscores an atypical kappa-restricted variant of POEMS syndrome and supports the role of CD38-directed therapy as an effective and well-tolerated option in plasma cell–mediated paraneoplastic disease. Early recognition of POEMS features in the setting of a small plasma cell clone can facilitate timely plasma cell–directed therapy and meaningful neurologic recovery.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"21 ","pages":"Article 100407"},"PeriodicalIF":0.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146189486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An enigmatic case of primary refractory myeloma: Mystery solved 一例原发性难治性骨髓瘤：谜团解开

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-02-03 DOI: 10.1016/j.cpccr.2026.100408

Kumar Nikhil M , Nathany Shrinidhi , Swaminathan Anusha , Singh Rekha , Dua Vikas , Bhargava Rahul

引用次数: 0

Malignant pleural mesothelioma in a young patient with neurofibromatosis 2 and acquired BAP1 loss: A case report 恶性胸膜间皮瘤合并神经纤维瘤2并获得性BAP1缺失1例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-01-29 DOI: 10.1016/j.cpccr.2026.100406

Jerry Kong , Jake Sharma , Joshua K. Sabari

{"title":"Malignant pleural mesothelioma in a young patient with neurofibromatosis 2 and acquired BAP1 loss: A case report","authors":"Jerry Kong , Jake Sharma , Joshua K. Sabari","doi":"10.1016/j.cpccr.2026.100406","DOIUrl":"10.1016/j.cpccr.2026.100406","url":null,"abstract":"<div><h3>Introduction</h3><div>Neurofibromatosis type 2 (NF2) is a rare genetic disorder resulting from germline loss of the <em>NF2</em> tumor suppressor gene characterized by the development of multiple benign central nervous system tumors. Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer arising from the pleura. We present a 32-year-old male with NF2 diagnosed with MPM found to have acquired <em>BAP1</em> loss.</div></div><div><h3>Case Report</h3><div>We present a 33-year-old male patient with previously known NF2 who was found to have <em>BAP1</em> and <em>NF2</em> mutant MPM. The patient denied history of asbestos exposure or chest radiation. He presented with a persistent cough and tachycardia for which he underwent a computed tomography angiogram of the chest which discovered pleural effusion and pleural nodules. After a complicated diagnostic course involving 2 negative biopsies, a 3rd surgical biopsy finally showed sarcomatoid MPM, and molecular testing revealed mutations in <em>BAP1</em> and <em>NF2</em>. The patient was initiated on dual checkpoint immunotherapy and has a durable response 14 months since treatment initiation.</div></div><div><h3>Conclusion</h3><div>This is the first case reported, to our knowledge, for which an NF2 patient was diagnosed with MPM at a young age and without known traditional risk factors. Somatic mutations in <em>NF2</em> are often observed in MPM, but germline <em>NF2</em> loss is not classically associated with MPM. However, in the setting of concomitant acquired <em>BAP1</em> loss, germline <em>NF2</em> loss could predispose a patient to MPM. This case highlights the importance of better understanding how genetic variants in tumor suppressor genes influence cancer risk.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"21 ","pages":"Article 100406"},"PeriodicalIF":0.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146189483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Durable local control after radiation therapy for oligometastatic uterine clear cell carcinoma: a case report 少转移性子宫透明细胞癌放射治疗后持久局部控制1例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-02-28 DOI: 10.1016/j.cpccr.2026.100413

Tala Mobayed , Lara Hilal , Jana Kobeissi , Racha Khodr , Ali Shamseddine , Bassem Youssef

{"title":"Durable local control after radiation therapy for oligometastatic uterine clear cell carcinoma: a case report","authors":"Tala Mobayed , Lara Hilal , Jana Kobeissi , Racha Khodr , Ali Shamseddine , Bassem Youssef","doi":"10.1016/j.cpccr.2026.100413","DOIUrl":"10.1016/j.cpccr.2026.100413","url":null,"abstract":"<div><h3>Introduction</h3><div>Clear cell carcinoma (CCC) of the uterus is a rare subtype of endometrial cancer, accounting for about 5% of cases and associated with poor prognosis. Limited data on CCC makes treatment challenging, with most guidelines based on retrospective studies. This case illustrates the use of radiation therapy for durable local control in a patient with oligometastatic uterine CCC.</div></div><div><h3>Case Presentation</h3><div>A 68-year-old woman was diagnosed with stage IA uterine CCC in March 2020. Following surgery, adjuvant chemotherapy, and brachytherapy, she developed an abdominal wall oligometastasis. Despite initial systemic treatment, her disease progressed with the appearance of a new lung nodule. She received definitive radiation therapy for the lung and abdominal wall oligometastases with complete resolution of both lesions on PET-CT scan. However, the patient developed systemic disease progression at distant sites 18 months later, for which she received further systemic therapy. Despite further disease progression, both irradiated sites (abdominal lesion and lung nodule) remained in complete remission with durable local control maintained for 25 months of follow-up.</div></div><div><h3>Conclusion</h3><div>Radiation therapy provided effective and durable local control in this case of oligometastatic uterine CCC. This suggests that definitive radiotherapy may be beneficial for managing oligometastatic CCC, though more research is needed to optimize treatment strategies. To our knowledge, there are no published reports describing the use of definitive radiotherapy for treating abdominal wall oligometastases from uterine CCC. This case is unique in demonstrating a durable complete response of this oligometastatic lesion following definitive external beam radiation (EBRT).</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"21 ","pages":"Article 100413"},"PeriodicalIF":0.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147397744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast-implant associated unicentric castleman disease: a case report 隆胸相关单中心castleman病1例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2026-03-01 Epub Date: 2026-01-03 DOI: 10.1016/j.cpccr.2026.100404

Saishravan Shyamsundar , Mateo Sarmiento Bustamante , Larissa Borys , Megan S. Lim , Adam Bagg , Mary Jo Lechowicz , Daisy Alapat , Amy Chadburn , Gordan Srkalovic , Frits van Rhee , Bridget Austin , Joshua D. Brandstadter , David C. Fajgenbaum

引用次数: 0

Well-differentiated papillary mesothelial tumor of the fallopian tube: A case report 输卵管高分化乳头状间皮瘤1例

IF 0.2

Current problems in cancer. Case reports Pub Date : 2025-12-01 Epub Date: 2025-11-26 DOI: 10.1016/j.cpccr.2025.100398

Hideko Kotani , Sohei Kitazawa , Hisae Kaneko , Mie Tasaka

{"title":"Well-differentiated papillary mesothelial tumor of the fallopian tube: A case report","authors":"Hideko Kotani , Sohei Kitazawa , Hisae Kaneko , Mie Tasaka","doi":"10.1016/j.cpccr.2025.100398","DOIUrl":"10.1016/j.cpccr.2025.100398","url":null,"abstract":"<div><div>Well-differentiated papillary mesothelial tumor (WDPMT) is a rare mesothelial neoplasm that typically arises in the peritoneum of women of reproductive age and generally follows an indolent course, although occasional recurrence or malignant transformation has been reported. WDPMT of the fallopian tube is extremely uncommon. We report the case of a 46-year-old woman with long-standing menorrhagia who underwent total abdominal hysterectomy with bilateral salpingectomy for uterine leiomyomas, during which a solitary 5-mm nodule was incidentally identified on the left fallopian tube. Histological examination showed fibrovascular cores lined by cuboidal mesothelial cells with minimal atypia and no stromal invasion, while immunohistochemistry revealed WT1 and calretinin positivity, estrogen receptor and progesterone receptor negativity, weak focal PAX8 staining, and retained nuclear expression of BRCA1-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP). These findings supported a diagnosis of WDPMT. This case adds to the limited literature on fallopian tube WDPMT and highlights the importance of recognizing this rare entity and considering long-term follow-up, given its generally indolent but occasionally unpredictable behavior.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"20 ","pages":"Article 100398"},"PeriodicalIF":0.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145693901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Postmenopausal bleeding and hematometra revealing uterine carcinosarcoma 绝经后出血及子宫积血显示子宫癌肉瘤

IF 0.2

Current problems in cancer. Case reports Pub Date : 2025-12-01 Epub Date: 2025-11-28 DOI: 10.1016/j.cpccr.2025.100399

Ridwana Maher Manna , Sumyta Rahman , Nomaan Hassan Khan , Sabrina Nahin , Raihana Ferdousi , Mohammad Delwer Hossain Hawlader , Mohammad Ashraful Amin

引用次数: 0

Primary advanced malignant melanoma of the uterine cervix treated with a combination of nivolumab and concurrent radiotherapy: A case report 纳武单抗联合放射治疗原发性晚期宫颈恶性黑色素瘤：1例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2025-12-01 Epub Date: 2025-11-21 DOI: 10.1016/j.cpccr.2025.100396

Norihito Kamo , Shigenori Furukawa , Asami Kato , Chikako Okabe , Hideki Miura , Tetsu Sato , Shu Soeda , Keiya Fujimori

{"title":"Primary advanced malignant melanoma of the uterine cervix treated with a combination of nivolumab and concurrent radiotherapy: A case report","authors":"Norihito Kamo , Shigenori Furukawa , Asami Kato , Chikako Okabe , Hideki Miura , Tetsu Sato , Shu Soeda , Keiya Fujimori","doi":"10.1016/j.cpccr.2025.100396","DOIUrl":"10.1016/j.cpccr.2025.100396","url":null,"abstract":"<div><div>Malignant melanoma accounts for 1–4 % of all gynecological malignancies, with most cases originating in the vulva and/or vagina. Primary malignant uterine melanomas are rare. Although there are reports of initial treatment with nivolumab and combination therapy with nivolumab and radiotherapy for recurrent lesions, no standardized treatment protocol has been established. This case report describes a 74-year-old woman diagnosed with International Federation of Gynecology and Obstetrics stage IV primary malignant melanoma of the cervix. Nivolumab and radiotherapy were concurrently administered to the primary lesion, resulting in tumor mass reduction. However, new pelvic lymph node metastases were observed at 6 months. The same combination therapy was administered but proved ineffective, leading to disease progression and death. To our best knowledge, this is the first report on the combined use of immune checkpoint inhibitors and radiotherapy as the initial treatment for primary malignant melanoma of the cervix. In advanced cases, initial treatment may result in primary lesion reduction and symptom control.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"20 ","pages":"Article 100396"},"PeriodicalIF":0.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145623643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effective treatment of early triple-negative breast cancer in a patient with sickle cell disease through chemotherapy and immune checkpoint inhibitor therapy: The keynote 522 regimen 通过化疗和免疫检查点抑制剂治疗镰状细胞病患者早期三阴性乳腺癌的有效治疗：基调522方案

IF 0.2

Current problems in cancer. Case reports Pub Date : 2025-12-01 Epub Date: 2025-09-16 DOI: 10.1016/j.cpccr.2025.100393

Luise Josefine Froessl, Stevany Saxon-Filipe, Siayareh Rambally, Samira Syed

引用次数: 0